Abstract
Background
New cancer treatments, such as immune checkpoint inhibitors (ICIs), can improve survival and health-related quality of life (HRQoL) in patients with cancer. Although long-term monitoring of HRQoL has been shown to improve survival, integration of HRQoL into everyday practice remains poorly documented.
Objective
This study describes experiences and expectations of patients treated with ICIs regarding a discussion of HRQoL with health care professionals (HCPs) in cancer management.
Methods
This cross-sectional study was conducted in an online patient community (Carenity) in France. Patients treated with ICIs for cancer, included between September 2018 and January 2019, completed a questionnaire to assess the involvement of HCP in a discussion of HRQoL and when and what was discussed.
Results
Of 82 patients included (mean age: 56.9 years, 95% CI 54.2-59.6; 46 [56%] male; 34 [41%] with lung cancer), 62 (76%) reported discussing HRQoL at least once with HCPs, mainly general practitioners (54/82, 66%), oncologists (53/82, 65%), and hospital nurses (50/82, 61%). Around half (45/82, 55%) of the patients were satisfied with these discussions. Discussions with the oncologist were at the patient’s initiative (34/53, 64%). Discussions occurred primarily during follow-up visits (40/62, 65%), when adverse events occurred (30/62, 48%), and at treatment initiation (27/62, 32%). The most discussed dimensions were symptoms (48/62, 77%) and physical well-being (43/62, 69%). With respect to expectations, 54/82 (66%) patients considered oncologists as the most important HCPs for discussing HRQoL. These discussions were desirable throughout the care pathway, particularly at diagnosis (63/82, 77%) and when treatment was initiated (75/82, 92%) or changed (68/82, 83%). All HRQoL dimensions were considered important to discuss.
Conclusions
With only around half of the patients satisfied with HRQoL discussions, impactful HRQoL integration in clinical practice is critical. According to patients, this integration should involve mainly oncologists and general practitioners, should happen at every step of the care pathway, and should be extended to dimensions that are currently rarely addressed.
Reference42 articles.
1. Measuring health-related quality of life in patients with advanced cancer: a systematic review of self-administered measurement instruments
2. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses
3. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
4. Institut National du CancerPlan Cancer 2014-2019: Ministère des Solidarités et de la Santé2021-12-06Parishttps://solidarites-sante.gouv.fr/ministere/documentation-et-publications-officielles/rapports/sante/article/plan-cancer-2014-2019-4eme-rapport-au-president-de-la-republique
5. Haute Autorité de SantéÉvaluation des Médicaments: HAS-Santé20182021-12-06https://www.has-sante.fr/upload/docs/application/pdf/2021-03/doctrine_ct.pdf